Neuroanatomical alterations in Alzheimer disease. Alzheimer disease (AD) dementia affects 1 in 10 American families, and costs more than 90 billion dollars a year. Genetic and neuropathological evidence highlight a pathogenic role for Abeta, but the exact mechanism of how Abeta alters neural system function is uncertain. Nonetheless, Abeta is a key therapeutic target, and clinical trials using anti-Abeta approaches are underway. In the last 5 years of this grant we developed in vivo multiphoton microscopy techniques to image Abeta deposits in living transgenic mouse models, and discovered that anti-Abeta immunotherapy can clear existing plaques. Our goal is to test the hypothesis that Abeta induces synaptic failure, and to examine the consequences in both mice and humans of anti-Abeta immunotherapy.
Aim 1 examines hypotheses linking plaques with alterations in axons. Whether axonal dystrophies precede or follow plaque formation will be examined by imaging neuronal processes and plaques in young APP X YFP mice, then re-imaging them at later times. Transport of molecules and organelles near and distant from plaques will be examined in vivo using photoactivatable GFP constructs, introduced by AAV and Lentiviral vectors.
Aim 2 builds on the observation that postsynaptic elements, including dendritic spines, are lost near plaques. We will examine whether dendritic spines are less stable near plaques by imaging spine turnover. We will also determine if dendritic segments near plaques are functionally less active using a new genetically encoded reporter of synaptic activation, a 3'-5' UTR CAMKIIalpha/EGFP chimeric molecule. Passive immunization against Abeta, and application of oligomeric Abeta, will be used to test the hypothesis that Abeta is directly responsible for these axonal and dendritic pathologies.
The third aim proposes parallel studies of pre and postsynaptic structures in human AD autopsy material, including studies of autopsy tissue from individuals who had participated in the first immunotherapy trial, AN1792. Case reports show that plaque clearance occurs after vaccination. We have now organized a collaborative group of neuropathologists from multiple sites to examine systematically human tissue in which antibody mediated clearance of plaques has occurred. We believe that the questions posed in this application have high clinical relevance, and the severity and prevalence of the disease add urgency to these studies. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG008487-18
Application #
7490504
Study Section
Neurodegeneration and Biology of Glia Study Section (NDBG)
Program Officer
Snyder, Stephen D
Project Start
1989-08-01
Project End
2011-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
18
Fiscal Year
2008
Total Cost
$516,646
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Hopp, Sarah C; Bihlmeyer, Nathan A; Corradi, John P et al. (2018) Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain. J Neurochem 147:24-39
Farrar, Christian T; William, Christopher M; Hudry, Eloise et al. (2014) RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. PLoS One 9:e89901
Griciuc, Ana; Serrano-Pozo, Alberto; Parrado, Antonio R et al. (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78:631-43
Serrano-Pozo, Alberto; Muzikansky, Alona; Gómez-Isla, Teresa et al. (2013) Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 72:462-71
Macklin, Eric A; Blacker, Deborah; Hyman, Bradley T et al. (2013) Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. J Alzheimers Dis 36:475-86
Kopeikina, Katherine J; Polydoro, Manuela; Tai, Hwan-Ching et al. (2013) Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol 521:1334-53
Serrano-Pozo, Alberto; Gómez-Isla, Teresa; Growdon, John H et al. (2013) A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol 182:2332-44
Kopeikina, Katherine J; Wegmann, Susanne; Pitstick, Rose et al. (2013) Tau causes synapse loss without disrupting calcium homeostasis in the rTg4510 model of tauopathy. PLoS One 8:e80834
Kopeikina, Katherine J; Hyman, Bradley T; Spires-Jones, Tara L (2012) Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci 3:223-233
Wu, Hai-Yan; Hudry, Eloise; Hashimoto, Tadafumi et al. (2012) Distinct dendritic spine and nuclear phases of calcineurin activation after exposure to amyloid-? revealed by a novel fluorescence resonance energy transfer assay. J Neurosci 32:5298-309

Showing the most recent 10 out of 49 publications